As previously reported, Wedbush analyst Robert Driscoll downgraded Atreca to Neutral from Outperform with a price target of $1, down from $4. The firm notes Atreca discontinued lead asset ATRC-101 this quarter, citing financial considerations of next steps for the program. Wedbush views this as a necessary development considering a light cash runway, marginally extended to early 2024 with additional cuts to workforce and program expenditures. The company will focus current efforts on preclinical ADC program APN-497444, lead candidate selection for which is expected in 2023.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on BCEL: